Savara Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Savara Inc. on February 14, 2023, covering events occurring on February 13, 2023. The filing primarily addresses the appointment of a new executive officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and appointment details.
Material Changes
On February 13, 2023, Robert Lutz joined Savara Inc. as Chief Operating Officer. Mr. Lutz previously served as Chief Financial and Business Officer of iBio, Inc. (2021-2023) and held leadership roles at Strongbridge Biopharma plc and Shire Plc.
Management Commentary and Compensation Details
Mr. Lutz entered into an employment agreement with the following terms:
- Base Salary: $437,000 annually.
- Performance Bonus: Eligible for up to 40% of base salary, subject to performance objectives.
- Signing Bonus: One-time payment of $115,000.
- Equity Grants (Subject to Board Approval):
- Option to purchase 350,000 shares of common stock, vesting in 16 equal quarterly installments.
- 140,000 restricted stock units (RSUs), vesting in full on the two-year anniversary.
- Severance: Entitled to benefits upon termination without "cause," resignation for "good reason," or death/disability.
The filing contains no specific guidance, outlook, or discussion of risks beyond standard employment agreement terms.
Investor Verification Checklist
- Verify the Board's approval status of the proposed equity grants (350,000 options and 140,000 RSUs).
- Review the full text of the Executive Employment Agreement filed as Exhibit 10.1 for detailed definitions of "cause" and "good reason."
- Confirm the impact of the new COO appointment on Savara's operational strategy and pipeline development.